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Background 
Germline gain-of function (GOF) mutations in PIK3CD, encoding the catalytic p110δ subunit of phosphoinositide 
3-kinase (PI3K), result in hyperactivation of the PI3K–AKT–mechanistic target of rapamycin pathway and 
underlie a novel inborn error of immunity. Affected subjects exhibit perturbed humoral and cellular immunity, 
manifesting as recurrent infections, autoimmunity, hepatosplenomegaly, uncontrolled EBV and/or cytomegalo-
virus infection, and increased incidence of B-cell lymphoproliferation, lymphoma, or both. Mechanisms 
underlying disease pathogenesis remain unknown. 
Objective 
Understanding the cellular and molecular mechanisms underpinning inefficient surveillance of EBV-infected B 
cells is required to understand disease in patients with PIK3CD GOF mutations, identify key molecules required 
for cell-mediated immunity against EBV, and develop immunotherapeutic interventions for the treatment of this 
and other EBV-opathies. 
Methods 
We studied the consequences of PIK3CD GOF mutations on the generation, differentiation, and function of 
CD8+ T cells and natural killer (NK) cells, which are implicated in host defense against infection with herpes 
viruses, including EBV. 
Results 
PIK3CD GOF total and EBV-specific CD8+ T cells were skewed toward an effector phenotype, with exaggerated 
expression of markers associated with premature immunosenescence/exhaustion and increased susceptibility to 
reactivation-induced cell death. These findings were recapitulated in a novel mouse model of PI3K GOF 
mutations. NK cells in patients with PIK3CD GOF mutations also exhibited perturbed expression of 
differentiation-associated molecules. Both CD8+ T and NK cells had reduced capacity to kill EBV-infected B 
cells. PIK3CD GOF B cells had increased expression of CD48, programmed death ligand 1/2, and CD70. 
Conclusions 
PIK3CD GOF mutations aberrantly induce exhaustion, senescence, or both and impair cytotoxicity of CD8+ T 
and NK cells. These defects might contribute to clinical features of affected subjects, such as impaired immunity 
to herpesviruses and tumor surveillance. 
 
 
 
Phosphoinositide 3-kinase (PI3K) signaling is pivotal in regulating many cellular processes involved in 
lymphocyte biology, including differentiation, proliferation, apoptosis, metabolism, and effector function.1 In 
human subjects PIK3CD encodes the p110δ isoform of the catalytic subunit of PI3K. p110δ is expressed 
predominantly in hematopoietic cells and forms a heterodimer with the p85α regulatory subunit.2, 3 Ligation of 
molecules linked to tyrosine kinase activity, including CD8, T-cell receptor (TCR), and CD28, potentiates 
recruitment and activation of p110δ, resulting in activation of downstream effector molecules. PI3K activation is 
regulated by phosphatase and tensin homolog and SH2 domain-containing inositol 5′-phosphatase, which 
dephosphorylate substrates of p110δ.4, 5 
 
CD8+ T cells require changes in metabolism as a means of regulating their differentiation, proliferative capacity, 
effector function, and memory generation.6, 7 Mechanistic target of rapamycin (mTOR) is a metabolic checkpoint 
kinase activated by PI3K and plays a key role in regulating glycolysis.8, 9  After encounter with specific antigen, 
naive T cells can differentiate into effector cells, culminating in activation of the PI3K-AKT-mTOR pathway and 
a metabolic shift toward glycolysis. Previous studies demonstrated that mice expressing catalytically inactive 
p110δ exhibit defects in TCR signaling.10  Furthermore, CD8+ T-cell responses in these mice to Listeria 
monocytogenes infection11 and their migratory capacity were impaired.12 PI3K-AKT signaling also modulates the 
differentiation, development, and activation of NK cells. In p110δ-deficient mice, as well as in PI3K inhibitor–
treated human cells, attenuated p110δ signaling causes decreased NK cell numbers, terminal 
differentiation, cytokine production, cytotoxicity, and migration.13, 14, 15 
 
The importance of the PI3K-AKT pathway in modulating signals in lymphocytes is highlighted by various 
pathologic conditions that result from aberrant signaling through this pathway.16, 17  To date, more than 100 
subjects with heterozygous mutations in PIK3CDhave been described, with most having the recurrent E1021K 
mutation in the catalytic domain of p110δ. These mutations cause constitutive activation of the PI3K-AKT-
mTOR pathway and are thus gain-of-function (GOF) mutations.18, 19  Affected subjects present with clinical 
features, including recurrent respiratory tract infections, lymphadenopathy, impaired humoral immune responses, 
increased susceptibility to EBV and/or cytomegalovirus (CMV), autoimmunity, and increased incidence of B-
celllymphoproliferation, lymphoma, or both.18, 19, 20, 21 PIK3CD GOF mutations decrease total CD4+ T-cell 
frequencies and numbers of naive CD4+ and CD8+ T cells, with concomitant increases in numbers of effector 
memory CD8+ T cells.17, 18, 19, 20, 21, 22  Numbers of natural killer (NK) cells are also reduced in some 
subjects.17, 18, 19, 20 
 
To understand immune dysregulation and increased susceptibility to EBV-induced disease in patients with 
PIK3CD GOF mutations, we performed in-depth analysis of the differentiation, activation, and function of their 
CD8+ T cells and NK cells. Activating mutations in PIK3CDcause a premature immunosenescent/ exhaustion-
type phenotype of CD8+ T cells and altered differentiation of NK cells, resulting in impaired cytotoxicity of both 
cell subsets against EBV-infected B cells. These findings provide insight into some of the clinical features of 
PIK3CD GOF mutations, including impaired control of EBV and susceptibility to B-cell lymphoma. 
 
 
METHODS 
Clinical evaluation 
PBMCs were isolated from healthy anonymous blood donors obtained from the Australian Red Cross Service and 
patients with PIK3CD GOF mutations (Table I).19, 23, 24 Viral infection history of healthy donors was unknown. 
Whole blood was collected from Australian-based patients and sent immediately to the Garvan Institute of 
Medical Research. PBMCs were isolated and either analyzed fresh or cryopreserved and stored in liquid nitrogen 
until use. For patients outside of Australia, PBMCs were isolated and cryopreserved as single-cell suspensions as 
above, shipped to the Garvan Institute on dry ice, and then stored in liquid nitrogen until use. This study was 
approved by institutional human research ethics committees at the relevant institutions. 
 
T, B, and NK cell phenotyping 
PBMCs from healthy control subjects and patients with PIK3CD GOF mutations were labeled with mAbs 
against CD3, CD4, CD8, CD20, and CD56. CD8+ T-cell subsets were defined as naive T (TN; CD8+CD4−CCR7+ 
CD45RA+), central memory T (TCM; CD8+CD4−CCR7+CD45RA−), effector memory T (TEM; CD8+CD4−CCR7− 
CD45RA−), and terminally differentiated effector memory T expressing CD45RA (TEMRA; CD8+CD4−CCR7− 
CD45RA+) cells. B cells were defined as CD3−CD20+ cells, and NK cells were defined as CD3−CD56+ cells. 
Typing for HLA-A, HLA-B, and HLA-C was performed by the Australian Red Cross Service. PBMCs from 
patients with PIK3CD GOF mutations and healthy control subjects were stained with 20 μg/mL EBV-specific 
tetramers (Table E1) at 37°C for 20 minutes.25 
 
For phenotyping, cells were further stained with cell-surface and intracellular antibodies (Table E2). For Vβ 
repertoire staining, PBMCs were stained further with the IOTest Beta Mark kit (Beckman Coulter, Brea, Calif), 
according to the manufacturer's instructions. Data were acquired on an LSRII SORP (Becton Dickinson, 
Mountain View, Calif) and analyzed with FlowJo software (TreeStar, Ashland, Ore). Based on Boolean gating 
analysis, coexpression of CD57, KLRG1, and programmed cell death protein 1 (PD-1) was determined by using 
Prism 7 software (GraphPad Software, La Jolla, Calif). 
 
Analysis of CD8+ T-cell functional capacity in vitro 
Sorted TEM (CD8+CD4−CCR7−CD45RA−) and TEMRA(CD8+CD4−CCR7−CD45RA+) CD8+ T cells were cultured in 
96-well round-bottom plates (3 × 104 cells/well) with T-cell expansion and activation (TAE; anti-CD3, anti-
CD28, and anti-CD2 mAb) beads (Miltenyi Biotech, Bergisch Gladbach, Germany). After 5 days, supernatants 
were harvested and assayed for production of IFN-γ, TNF-α, IL-2, granzyme A, and granzyme B by using a 
cytometric bead array (Becton Dickinson, Franklin Lakes, NJ). For cytokineexpression, activated CD8+ T cells 
were restimulated with phorbol 12-myristate 13-acetate (PMA; 100 ng/mL)/ ionomycin (750 ng/mL) for 6 hours, 
with Brefeldin A (10 μg/ml; Sigma-Aldrich, St Louis, Mo), monensin (2 μmol/L; eBioscience, Waltham, Mass), 
and anti-CD107a (Becton Dickinson, Franklin Lakes, NJ) added after 2 hours. Cells were fixed and stained for 
expression of IFN-γ, TNF-α, IL-2 (BD Horizon, Mountain View, Calif), granzyme B (BD PharMingen, San Jose, 
Calif), and perforin (BioLegend, San Diego, Calif). Samples were acquired on an LSRII SORP (Becton 
Dickinson) and analyzed with FlowJo software. 
 
Cell proliferation 
PBMCs were labeled with carboxyfluorescein succinimidyl ester (2.5 μmol/L; eBioscience, Carlsbad, Calif) and 
then cultured at 1.2 × 105 cells per well with TAE beads (1 bead per 2 cells) with or without 50 U/mL IL-2 
(Millipore, Darmstadt, Germany) or 5 μg/mL PHA (Sigma-Aldrich) plus 50 U/mL IL-2 for 3 or 5 days. Cells 
were stained with Zombie Aqua Fixable Dye (BioLegend), fixed, and run on the LSR II Fortessa (Becton 
Dickinson). Data were analyzed with FlowJo software. 
 
Cytotoxic T-cell and NK cell killing assays (including T-cell line and NK lymphokine-activated killer cell 
generation) 
EBV-specific T-cell lines were generated from patient or control PBMCs, as previously described.26, 27   
Cytotoxicity and intracellular cytokine stimulation assays against autologous lymphoblastoid cell lines (LCLs) 
were performed after the third restimulation cycle. Sorted NK cells (CD3−CD56+) were stimulated with 100 
U/mL IL-2 in RPMI 1640/20% FCS, and cytotoxicity against autologous LCLs was assessed on day 10. 
 
NK and cytotoxic T-lymphocyte cytotoxicity was assessed by using a CytoTox 96 Non-Radioactive Cytotoxicity 
Assay (Promega, Madison, Wis), as previously described.19  Briefly, 10,000 target cells (LCLs) were plated at 
various effector/target ratios with NK cells (5:1 or 10:1) or cytotoxic T lymphocytes (2.5:1, 5:1, 7.5:1, or 10:1) in 
U-bottom plates at 37°C. After 4 hours, supernatants were collected and assayed to determine the amount 
of lactate dehydrogenase released on cell lysis by using colorimetry. Percentage cytotoxicity was determined by 
using the following equation from the manufacturer's instructions: 
 
% Cytotoxicity = Experimental value − (Corrected effector spontaneous + Corrected target spontaneous) × 100/ 
 
Corrected target maximum − Corrected target spontaneous. 
Sorting and culture of B cells 
Total B cells (CD20+, >98% purity) were sorted from PBMCs from healthy control subjects or patients with 
PIK3CD GOF mutations by using a FACSAria III (Becton Dickinson). B cells or LCLs were seeded at 
30,000 cells/well in a U-bottom plate and cultured in RPMI 1640/10% FCS or stimulated with 2.5 μg/mL CD40 
ligand (R&D Systems, Minneapolis, Minn) with or without 2.5 μg/mL anti-immunoglobulin. On day 3, cells were 
stained with mAbs to anti-CD48, HLA-DR(BD PharMingen), CD95 (BD Horizon), CD70, HLA-ABC, 
programmed death ligand (PD-L) 1−PE or PD-L2 (eBioscience) and run on an LSRII Fortessa (Becton 
Dickinson). 
Restimulation-induced cell death, RNA extraction, and quantitative PCR analysis 
Restimulation-induced cell death (RICD) was determined, as previously described.28, 29  TEM and TEMRA CD8+  
T cells were sorted (>98% purity) on a FACSAria III and cultured with TAE beads. On day 3, 100 U/mL IL-2  
was added, and cells were maintained for 10 days, replacing IL-2 every 3 days. On day 13, cells were counted and 
seeded with medium alone or medium with 1 μg/mL plate-bound α-CD3 mAb (UCHT1; Biogems, Westlake Village, 
Calif) plus 100 U/mL I-L2 or 20 ng/mL α-CD95 mAb (APO-1-3, Enzo Lifesciences, Farmington, NY) plus 100 
U/mL IL-2. Cells were then cultured overnight and stained with Zombie Live/Dead Fixable Aqua to determine the 
frequency of dead cells.28, 29  To assess Fas ligand (FASLG) mRNA expression, cells were stimulated for 4 hours  
with anti-CD3 plus 100 U/mL IL-2, and total RNA was then extracted. Quantitative polymerase chain reaction was 
performed by using the Light Cycler 480 Probe Master Mix and System (Roche, Mannheim, Germany).  
FASLG(forward: 5′-CAGAAGGAGCTGGCAGAACT-3′; reverse: 5′-TGGCCTATTTGCTTCTCCAA-3′) and 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) primers (forward: 5′-CTCTGCTCCTCCTGTTCGAC-3′; 
reverse: 5′-ACGACCAAATCCGTTGACTC-3′) were obtained from Integrated DNA Technologies (Coralville, 
Iowa). Expression of Fas ligand was determined relative to expression of GAPDH. 
Murine flow cytometric phenotyping 
Spleens of wild-type or Pik3cdE1020K  GOF mice were harvested, prepared, and stained for flow cytometry, as 
previously described,30 by using the mAbs listed in Table E3  Data were acquired on either the LSRII SORP or 
LSR Fortessa (Becton Dickinson) and analyzed with FlowJo software. All data are representative of 2 or more 
experiments, as indicated. All animal studies were approved by the St Vincent's Animal Ethics Committee. 
 
Murine in vitro cultures 
Sorted Pik3cdE1020K GOF or wild-type naive CD8+ T cells were cultured in flat-bottom 96-well plates coated with 
anti-CD3 (4 μg/mL; BioLegend) in RPMI 1640 (Life Technologies, Grand Island, NY) supplemented with 10% 
FCS (Life Technologies) at 0.5 × 106 cells/mL. After 4 days, cells were stimulated with PMA (50 ng/mL) and 
ionomycin (375 ng/mL) for 6 hours. Brefeldin A (10 μg/mL) was added to each well at 2 hours of culture. Cells 
were then harvested, washed, and stained with Zombie Aqua Viability Dye (BioLegend). CD8+ T cells were 
fixed, permeabilized, and stained with mAbs to anti–TNF-α and anti–IFN-γ and analyzed by using flow 
cytometry. 
Statistical analysis 
For single comparisons of independent groups, a Mann-Whitney test was performed. For multiple comparisons, 
2-way ANOVA or multiple t tests were applied as follows. Analyses were performed with GraphPad Prism 
software. 
 
 
RESULTS 
Patients with PIK3CD GOF mutations present with features of EBV-associated disease 
In this study we investigated 39 patients from 28 families (18 male and 21 female patients) with activating 
mutations in PIK3CD. The E1021K mutation was found in 28 of 39 patients.19, 31  The other mutations identified 
in patients in this study (ie, G124D, N334K, E525K, and E1025G) have been reported previously and confirmed 
to be GOF mutations.19, 23, 24  Patients' ages ranged from 4.5 to 67 years (mean, 20.1 years), with patients 
originating from a variety of ethnicities (Table I). As control subjects, we analysed PBMCs from 38 healthy 
donors whose ages ranged from 10 to 71 years (mean, 38.0 years). Overall, 19 subjects were confirmed to be 
EBV+ by using PCR, whereas 6 subjects were CMV+ (Table I). The 6 CMV+ subjects were also EBV+. Four 
patients had B-celllymphoma (2 EBV+ subjects, Table I). The incidences of EBV/CMV infection/viremia and B-
cell malignancy in this cohort are comparable with that reported previously.20 
 
CD8+ T cells are increased and are enriched as effector memory cells in patients with PIK3CD GOF 
mutations 
To investigate the effect of PIK3CD GOF mutations on cytotoxic lymphocytes, we first determined proportions 
of peripheral blood T-cell populations and subsets. Compared with healthy control subjects, patients with 
PIK3CD GOF mutations had increased frequencies of CD8+ T cells and a corresponding decrease in numbers 
of CD4+ T cells, thereby yielding a significantly inverted CD4/CD8 ratio (Fig 1, A-C). The CD4/CD8 ratio tends 
to increase with age, being approximately 1.5 to 2.0 for 20-year-olds and gradually increasing to 2.5 to 3.0 by 
80 years of age.32 Therefore one explanation for the decreased CD4/CD8 ratio in our cohort could be that 
approximately 60% of patients in our study were aged 20 years or less (Table I). To formally test this, we 
determined the CD4/CD8 ratio for a range of healthy donors and patients with PIK3CD GOF mutations as a 
function of age. As shown in Fig 1, D, a decreased CD4/CD8 ratio was observed consistently for all age groups of 
patients with PIK3CD GOF mutations compared with control subjects, establishing that this parameter was not 
influenced by an enrichment of younger patients in our study cohort versus the healthy control subjects. 
 
CD8+ T cells can be divided into naive and memory subsets based on differential expression of CCR7 and 
CD45RA.33 A population of T cells, termed stem cell memory-like T (TSCM) cells, with self-renewal properties 
and the capacity to form effector memory cells on antigen encounter, has also been identified. Like naive cells, 
TSCM cells are also CCR7+CD45RA+. However, TSCMcells can be distinguished from naive cells by their 
expression of CD95.34 Thus in our analyses we refer to CD45RA+CCR7+CD8+ T cells as TN/TSCM cells. Applying 
this analysis revealed an expansion of TEM cells (CCR7−CD45RA−) with a corresponding reduction in TN/TSCM 
(mostly naive) cells in patients with PIK3CD GOF mutations compared with healthy control subjects. The 
proportions of TCM (CCR7+CD45RA−) cell and TEMRA (CCR7−CD45RA+) cell subsets in the patients were in the 
normal range (Fig 1, E and F). Similarly, PIK3CD GOF mutations resulted in fewer TN CD4+ cells but 
significantly increased proportions of TCM CD4+ cells (not shown). 
 
CD8+ T cells from patients with PIK3CD GOF mutations are skewed toward a phenotype consistent with 
functional exhaustion and senescence 
CD57 expression can delineate populations of senescent CD8+ T and NK cells.35, 36  Previous reports suggested 
CD8+ T cells in patients with PIK3CDGOF mutations are predominantly of a senescent phenotype, as evidenced 
by increased proportions of CD57+ cells.19, 20, 21, 22   After chronic infection and therefore constant antigen 
stimulation, CD8+ T cells can also adopt a state of exhaustion, which is defined as the progressive and 
hierarchical loss of effector function, a concomitant acquisition of inhibitory or regulatory surface receptors, and 
alterations in cytokine, chemotactic, survival, and metabolic signaling pathways.37, 38 
 
For these reasons, we first performed comprehensive phenotypic analysis of total CD8+ T cells in patients 
with PIK3CD GOF mutations and control subjects. To achieve this, we quantified expression of surface 
molecules associated with CD8+ T-cell activation (CD38, HLA class I, and HLA class II),39, 40differentiation, 
exhaustion (CD95, CD160, KLRG1, and PD-1),38, 41, 42, 43, 44, 45 and senescence (CD57).35, 36   The proportions of 
total PIK3CD GOF CD8+T cells that expressed these molecules were significantly increased compared with those 
in control subjects (Fig 2). 
 
Next, we determined expression of these molecules on CD8+ T cells at distinct stages of differentiation. CD160 
expression did not differ among the CD8+ T-cell subsets examined, whereas expression of CD95 and KLRG1 was 
significantly increased on naive and TCM cells, respectively. In contrast, the other molecules examined were 
detected on significantly greater proportions of TN, TCM, TEM, and TEMRA CD8+ T-cell subsets (Fig 2). Thus the 
increased expression of these markers of differentiation on CD8+ T cells did not simply reflect accumulation of 
TEM cells (Fig 1, E). Rather, these data reveal the general senescent and/or exhausted-type state of most subsets of 
CD8+ T cells in patients with PIK3CDGOF mutations, which is consistent with analyses of much smaller cohorts 
of patients with PIK3CD GOF mutations.19, 22 
 
We also examined expression of 2B4 (CD244) and NKG2D (CD314), molecules implicated in CD8+ T and NK 
cell–mediated control of EBV-infected B cells.26, 46, 47 2B4 is also a marker of CD8+ T-cell exhaustion.37, 38 2B4 
was increased on total T cells because of upregulation on TN, TCM, and TEM CD8+ cells (Fig 2, B). In contrast, 
relative NKG2D expression was only modestly increased on naive CD8+ T cells (Fig 2, J). 
 
In patients with HIV or chronic hepatitis B or C virus infection, coexpression of a suite of regulatory molecules 
on CD8+ T cells correlates with exhaustion and impaired effector function of these cells.38, 41, 44, 48  Therefore we 
investigated coexpression of PD-1, KLRG1, and CD57 on CD8+ T cells from patients with PIK3CD GOF 
mutations and control subjects. Strikingly, a larger frequency of PIK3CD GOF CD8+ T cells coexpressed CD57, 
2B4, and KLRG1 compared with control subjects in which few coexpressed these 3 receptors (Fig 2, K). 
Importantly, the “exhausted-type” phenotype of PIK3CD GOF CD8+ T cells appeared to result directly from 
the genetic mutation rather than pathogen or chronic viral infection because similar phenotypic characteristics of 
CD8+ T cells were observed in patients who were EBV naive or who had mild or chronic EBV viremia. 
 
We also analyzed the Vβ repertoire of the different subsets of CD8+ T cells by determining expression of 
individual TCR Vβ chains through flow cytometry. TCR Vβ repertoires of patients with PIK3CD GOF mutations 
and control subjects were similar. Differences in the most predominant Vβ chain use between subjects likely 
reflects the diversity of pathogens encountered and the immunogenicity of the antigenic peptides they encode (Fig 
E1).  Collectively, our results indicate that PIK3CD GOF mutations result in sustained and exaggerated activation 
of polyclonal CD8+ T cells, yielding prematurely immunosenescent and exhausted-type CD8+ T cells. 
 
EBV-specific CD8+ T cells are skewed toward a TEM phenotype in patients with PIK3CD GOF mutations 
Next, we investigated whether generation of EBV-specific CD8+ T cells was affected by PIK3CD GOF 
mutations. In 14 subjects in whom HLA class I typing was available, PBMCs from patients and HLA-matched 
control subjects were stained ex vivo with MHC class I peptide tetramers and dextramers to identify EBV-specific 
T cells ( Table E1). Comparable frequencies of EBV-specific CD8+ T cells were detected in patients with 
PIK3CD GOF mutations and healthy HLA-matched control subjects (Fig 3, A). In healthy donors most EBV-
specific CD8+ T cells have a TCM or TEM phenotype (Fig 3, B).49, 50   In contrast, most EBV-specific CD8+ T cells 
in patients with PIK3CD GOF mutations exhibited a TEM phenotype (Fig 3B). Similar to total polyclonal CD8+ T 
cells, expression of CD57, KLRG1, CD160, CD95, CD38, PD-1, 2B4, and NKG2D was increased significantly 
on EBV-specific CD8+ T cells from patients with PIK3CD GOF mutations compared with healthy control 
subjects. Moreover, the vast majority of EBV-specific T cells in patients with PIK3CD GOF mutations 
coexpressed the regulatory receptors 2B4, KLRG1, and/or CD57, whereas in healthy control subjects more than 
60% of EBV-specific T cells lacked expression of these markers. These data suggest that, akin to total PIK3CD 
GOF CD8+ T cells and CD8+ T cells specific for HIV, hepatitis B and hepatitis C virus,38, 41, 48, 51 EBV-
specific PIK3CD GOF T cells acquire a phenotype consistent with premature senescence, exhaustion, or both and 
impaired effector function. 
 
PIK3CD GOF mutations alter the functionality of CD8+ T cells 
To determine the effect of PIK3CD GOF mutations on CD8+ T-cell function, we first assessed proliferation.  Cell 
division, as measured based on carboxyfluorescein succinimidyl ester dilution, after in vitro stimulation with 
PHA/IL-2 or mAbs specific for CD2, CD3, and CD28 with or without IL-2 was unaffected by PIK3CD GOF 
mutations (Fig 4, A and B). Although these data appear to contrast previous studies that observed decreased 
proliferation of PIK3CD GOF T cells in response to CD3/CD28 stimulation, Lucas et al19reported that inclusion 
of anti-CD2 mAbs could overcome defective proliferation of PIK3CD GOF T cells. Thus our data are concordant 
with previously published findings. 
 
Expression of granzymes A, B, and K and perforin, components of the cytolytic machinery, was increased in total 
and EBV-specific (Fig 4, E and F, and Fig E2, B) PIK3CD GOF CD8+ T cells. Proportions of total PIK3CD GOF 
CD8+ T cells expressing IFN-γ or CD107a were increased (Fig 4, G and H) and those expressing IL-2 were 
decreased (Fig 4, I) on ex vivo stimulation with PMA/ionomycin. 
 
To ascertain whether TEM cell expansion was responsible for the observed CD8+T-cell dysfunction in patients 
with PIK3CD GOF mutations, we sorted TEM and TEMRA subsets, stimulated them with anti-CD2/CD3/CD28 
mAbs, and measured cytokine expression and degranulation. A higher proportion of TEM cells from patients 
with PIK3CD GOF mutations expressed IFN-γ and CD107a compared with those from control subjects; however, 
a reduced proportion of these cells expressed IL-2 (Fig E2, C). Expression of granzyme B and perforin were not 
significantly different in activated TEM cells from patients and control subjects (Fig E2, C). In contrast, the 
frequency of IFN-γ–expressing TEMRA cells was reduced by PIK3CD GOF mutations (Fig E2, D). There were 
trends for greater expression of CD107a, granzyme B, and IL-2 in TEMRA cells from patients with PIK3CD GOF 
mutations compared with control subjects, but these differences did not reach statistical significance. Our flow 
cytometric analysis of CD8+ T-cell subsets was confirmed when secretion of effector molecules was determined, 
showing that TEM cells from patients with PIK3CD GOF mutations secreted larger quantities of cytokines and 
cytolytic molecules compared with healthy subjects (Fig E2, C). The phenotypic differences observed in total 
CD8+ T cells was largely observed when examining the TEM compartment, such as significant increases in the 
expression of CD57, PD-1, CD38, 2B4, and HLA class I and II. 
 
Next, we addressed the effect of PIK3CD GOF mutations on CD8+ T cell–mediated immunity to EBV. To test 
this, we generated CD8+ T-cell lines against autologous EBV-transformed B-LCLs. EBV-specific CD8+ T-cell 
lines from patients with PIK3CD GOF mutations exhibited reduced cytotoxicity toward autologous LCLs at 
effector/target ratios of between 5:1 and 10:1 (Fig 4, J and K). Thus PIK3CD GOF CD8+ T cells exhibit 
dysregulated cytokine expression and defective cytotoxic function against EBV-LCLs. 
 
Increased RICD of PIK3CD GOF CD8+ T cells 
RICD is an apoptotic mechanism used to limit effector T-cell expansion, thereby restricting the risk of 
nonspecific damage to the host. Defects in this process have been proposed to contribute to host tissue damage 
and unrestrained T-cell accumulation in patients with X-linked lymphoproliferative disease because of SLAM-
associated protein deficiency.29 RICD is triggered in effector cells by using TCR ligation, which upregulates 
proapoptotic Fas ligand to induce autocrine cell death. Thus Fas ligand expression correlates with RICD 
susceptibility.28, 29  To ascertain whether RICD was affected, TEM and TEMRAcells were sorted from patients 
with PIK3CD GOF mutations and healthy control subjects stimulated with CD2, CD3, and CD28 mAbs, with IL-
2 being added on day 3. Ten days after addition of IL-2, cells were stimulated with either α-CD3 mAb to induce 
RICD or α-CD95 mAb to determine the sensitivity to CD95-mediated apoptosis. Increased RICD was observed in 
TEM, but not TEMRA, cells from patients with PIK3CD GOF mutations compared with corresponding cells from 
control subjects (Fig 4, K). This correlated with greatly increased expression of FASLG in cells from patients 
with PIK3CD GOF TEM mutations relative to control TEM cells (Fig 4, L). There was also greater death of TEM, but 
not TEMRA, cells induced by a suboptimal concentration of anti-CD95 mAbs (Fig 4, M). Collectively, these data 
indicate that PIK3CD GOF mutations render TEMcells more susceptible to apoptosis induced by RICD or 
engagement of CD95. 
 
PIK3CD GOF mutations dysregulate NK cell differentiation and function 
NK cells also play key roles in host defense against viral infection, including herpesviruses; for instance, NK cells 
control EBV in patients with infectious mononucleosis.52, 53   For this reason, we examined the NK cell 
compartment of patients with PIK3CD GOF mutations. NK cell frequencies as a percentage of peripheral blood 
lymphocytes (Fig 5, A) and proportions of CD56bright and CD56dim subsets were unaltered by PIK3CD GOF 
mutations. However, further analysis revealed that expression of CD57, CD158a/g/h, CD16, granzyme B, 
perforin, and HLA class I was significantly increased on both CD56bright  and CD56dim NK cell subsets from 
patients with PIK3CD GOF mutations (Fig 5, A-J). NKG2A was also upregulated on CD56dim and KLRG1 was 
increased on CD56brightPIK3CD GOF NK cells (Fig 5, D and F). In contrast, PIK3CD GOF had no effect on 2B4 
or NKG2D expression. 
 
Lymphokine-activated killer cells were generated from patients and control subjects and then stimulated with 
autologous EBV-LCLs to determine whether NK cell cytotoxic function was affected by PIK3CD GOF mutations 
and altered effector phenotype. PIK3CD GOF lymphokine-activated killer cells exhibit decreased cytotoxicity in 
response to autologous LCLs (Fig 5, K and L). Thus NK cells in patients with PIK3CD GOF mutations exhibit 
dysregulated expression of key regulatory molecules and reduced cytotoxic function. 
 
Altered expression of regulatory ligands on B cells in patients with PIK3CD GOF mutations 
To extend our analysis of defects in pathways controlling cytotoxicity of NK cells and CD8+ T cells, we 
determined expression of ligands of 2B4 (CD48), PD-1 (PD-L1 and PD-L2), and CD27 (CD70), which have been 
shown to be dysregulated on B-cell lymphomas and/or EBV-infected B cells,47, 54, 55 on B cells from patients 
with PIK3CD GOF B mutations. We analyzed primary B cells and LCLs before and after stimulation with CD40 
ligand/anti-immunoglobulin. CD48 and CD70 were upregulated on PIK3CD GOF B cells relative to control B 
cells ex vivo (Fig 6, A). On stimulation, primary B cells upregulated PD-L1, PD-L2, and CD70 (Fig 6, A), with 
significantly higher expression on activated  
 
Heightened expression of CD48, PD-L1, PD-L2, and CD70 was also observed for unstimulated LCLs from 
patients with PIK3CD GOF mutations compared with control LCLs, with further upregulation on PIK3CD GOF 
LCLs after activation CD40 ligand/anti-immunoglobulin (Fig 6, B). Similar results were obtained when we 
assessed expression of HLA class I, HLA class II, and CD95 on resting and activated primary B cells and LCLs 
from healthy control subjects and patients with PIK3CD GOF mutations (Fig E3, A and B).  Taken together, these 
findings establish that PIK3CD GOF B cells express increased levels of ligands that regulate cytotoxicity of 
CD8+ T cells and NK cells. 
 
Mice bearing a PI3K p110δ GOF mutation phenocopy defects in human PIK3CDGOF CD8+ T cells 
Many patients with PIK3CD GOF mutations have chronic or severe herpesvirus infections.19, 20   Thus to confirm 
that the changes we observed in CD8+ T-cell differentiation were cell intrinsic and not secondary to pathogen 
infection, we generated a mouse model. We used CRISPR/Cas9-mediated gene editing to introduce a 
heterozygous glutamic acid (E) to lysine (K) substitution at amino acid number 1020 of the murine PI3K 
p110δ protein. This corresponds to the common E1021K mutation found in approximately 75% of patients 
with PIK3CDGOF mutations. The CD8+ T-cell compartment in the spleens of young (8-12 weeks) and aged 
(33 weeks) Pik3cdE1020K mice recapitulated the phenotype observed in patients with PIK3CD GOF mutations. 
Thus there were significantly reduced proportions of naive and corresponding increased proportions of central 
memory and effector memory CD8+ T cells in Pik3cdE1020K mice compared with littermate control mice (Fig 7, A-
C). These differences were exacerbated with age and also evident in blood (Fig 7, A-C). Functional analysis 
demonstrated increased production of IFN-γ and TNF-α by in vitro cultured naïve Pik3cdE1020KCD8+ T cells 
compared with control cells (Fig 7, D). This initial analysis of our novel in vivo model of human disease caused 
by PI3K p110δ GOF has established that dysregulation of CD8+ T-cell responses occurs independently of 
infection or immunization. 
 
 
DISCUSSION 
Activating mutations in PIK3CD underlie a novel disease of immune dysregulation. The spectrum of clinical 
features in patients with PIK3CD GOF mutations includes recurrent respiratory tract infections, 
lymphadenopathy, autoimmunity, EBV viremia, and B-cell lymphoma, many of which are EBV+.20, 21  Although 
the role and requirements of PI3K signaling in the setting of lymphocyte development, tolerance, and immunity 
have been established from studies of genetically modified mice, the mechanisms contributing to disease in 
patients with PIK3CD GOF mutations remain incompletely defined. Here we have focused on the development 
and effector function of CD8+ T and NK cellswith a view of understanding aspects of immune dysregulation and 
susceptibility to EBV-induced disease. 
 
The immunologic phenotype of patients with PIK3CD GOF mutations includes an expansion of CD8+ T cells 
skewed toward a TEM phenotype and a concomitantly reduced CD4/CD8 ratio.17, 18, 19, 20, 21, 22   We have now 
substantially confirmed and extended these findings in a very large cohort of patients (n = 39) by discovering 
that surface receptors, including CD57, 2B4, CD160, PD-1, KLRG1, and HLA class I, are upregulated on 
CD8+ T-cell subsetsfrom patients with PIK3CD GOF mutations. Furthermore, CD8+ T cells from patients 
with PIK3CD GOF mutations exhibited increased expression of granzyme B and perforin, reduced expression of 
IL-2, increased apoptosis, and impaired cytotoxicity. The phenotype of CD8+ T cells in patients 
with PIK3CDGOF mutations is reminiscent of exhausted or senescent-type CD8+ T cells observed after chronic 
or persistent viral infection in mice56 and human subjects,38, 41, 42, 43, 44, 45, 48, 51, 57  or in patients with other 
monogenic immune dysregulatory conditions, including dedicator of cytokinesis 8 (DOCK8)deficiency58 
and Evan syndrome caused by mutations in tripeptidyl peptidase 2 (TPP2).40 Mouse models of 
persistent lymphocytic choriomeningitis virusinfection have demonstrated that CD8+ T-cell function is 
compromised by ongoing viral stimulation, such that upregulation of inhibitory receptors and altered expression 
of effector cytokines underpins defective behavior of these cells.37 Thus acquisition of an exhausted- or senescent-
type phenotype by CD8+T cells from patients with PIK3CD GOF mutations likely explains their impaired 
cytotoxicity, potentially resulting in reduced immunosurveillance of EBV-infected B cells and increased 
incidence of EBV-associated disease.21 The exhausted or senescent phenotype and function of CD8+ T cells in 
patients with chronic infections, such as HIV, CMV, or hepatitis B or C virus, have been proposed to result from 
constant activation by persistent viral antigen.37, 38, 57   It is likely that these parallel features of exhausted- or 
senescent-type CD8+ T cells in patients with PIK3CD GOF mutations results from constitutive PI3K activation in 
these cells, essentially mimicking ongoing signaling through the TCR and costimulatory receptors rather than 
being secondary to recurrent or chronic pathogen infections. This is supported by the consistent exhausted- or 
senescent-type phenotype of CD8+ T cells in EBV-naive subjects, as well as patients with mild and chronic EBV 
viremia, coupled with the finding of a similar CD8+ T-cell phenotype in 
unimmunized/uninfected Pik3cdE1020K mutant mice. 
 
PIK3CD GOF mutations result in constitutive hyperactivation of the PI3K-AKT-mTOR pathway, thereby 
promoting aerobic glycolysis.19 Previous studies demonstrated a link between aerobic glycolysis and 
susceptibility to RICD.28 We also found increased susceptibility of CD8+ T cells from patients with PIK3CDGOF 
mutations to RICD. Thus this altered metabolic state might partially cause accelerated T-cell effector generation, 
limited effector function, and increased sensitivity to RICD, culminating in the phenotype of CD8+ T-cell 
dysfunction. Interestingly, susceptibility to RICD was observed for PIK3CD GOF TEM, but not TEMRA, CD8+ T 
cells. This correlated with selectively increased expression of FASLG by PIK3CD GOF TEM cells. Interestingly, 
HIV-specific TEM cells preferentially undergo greater spontaneous and CD95-mediated apoptosis than other 
CD8+ T-cell subsets; this was associated with increased expression of PD-1, CD95, and CD57. 43, 44   Remarkably, 
TEM cells from patients with PIK3CDGOF mutations expressed the highest levels of PD-1, CD95, and CD57 of 
all CD8+ T-cell subsets examined. This phenotype of PIK3CD GOF TEM cells, coupled with preferential induction 
of high levels of FASLG in PIK3CD GOF TEMcells and the requirement for Fas/Fas ligand interactions to regulate 
RICD,29 likely explains increased RICD in these, but not PIK3CD GOF TEMRA, cells. These findings also 
highlight that analysis of immune dysregulatory conditions caused by monogenic mutations can greatly inform 
our knowledge of similar immunopathologies occurring in the general population induced by extrinsic factors, 
such as infectious agents. This further underscores the utility of studying patients with PIK3CD GOF mutations as 
a valuable means of dissecting pathways and mechanisms regulating immunosenescence.21  Our findings, 
combined with those associating aerobic glycolysis with RICD,28 strongly support the utility of inhibitors of the 
PI3K pathway as therapeutic modalities for treating patients with PIK3CD GOF mutations. Indeed, treatment 
with the mTOR inhibitor rapamycin or the recently developed PI3K p110δ inhibitor leniolisib reduced the 
proportions of circulating CD57+ T cells in a short-term trial of patients with PIK3CD GOF mutations (Edwards, 
Tangye, and Uzel).19, 22 
 
Upregulation of molecules, including CD57, KLRG1, CD16, and killer cell immunoglobulin-like receptors (eg, 
CD158a/g/h), as well as the effector molecules granzyme B and perforin, is consistent with maturation of NK 
cells from a CD56bright to a CD56dim phenotype.59  Stepwise reductions in NKG2A and increases in killer cell 
immunoglobulin-like receptor expression have been shown to correlate with NK cell terminal differentiation 
and IFN-γ production.60NK cells were present in normal proportions in patients with PIK3CD GOF mutations, 
with no effect on the distribution of cells between the CD56bright and CD56dim compartments. However, the 
activation status of the NK cells was aberrant, as indicated by increased expression of CD57, CD16, NKG2A, and 
CD158a/g/h and reduced cytotoxicity toward EBV-infected B cells. This dysregulated pattern of receptor 
expression might have an adverse effect on NK cell function in these patients, such as the observed reductions in 
cytotoxicity against EBV-LCLs. Our findings are largely consistent with very recently published findings that 
also reported normal or near-normal proportions of total NK cells, normal proportions of CD56hi and 
CD56dim subsets of NK cells, increased expression of NKG2A on CD56dim NK cells, and impaired cytotoxicity of 
NK cells from patients with PIK3CD GOF mutations.61 Interestingly, we observed increased expression 
of granzymes and perforin by PIK3CD GOF CD8+ T cells and NK cells but impaired cytotoxicity. These 
paradoxical findings can be explained by the recent discovery that NK cells from patients with PIK3CD GOF 
mutations exhibit poor polarization of the lytic machinery to the microtubule organizing center, a requisite step 
for cytotoxic function.61  Thus our phenotypic and functional data suggest that PIK3CD GOF mutations 
compromise the mobilization and polarization of the lytic machinery in cytotoxic lymphocytes, impairing their 
cytotoxic effector function, despite increased expression of cytotoxic mediators. 
The significance of an altered phenotype of CD8+ T cells, NK cells, and B cells in patients with PIK3CD GOF 
mutations is highlighted by the known functions of several of these receptor/ligand pairs in host defense against 
EBV. 2B4 can act as an inhibitory or activating receptor,46, 47 the outcome of which depends on its level of 
expression and engagement by CD48, as well as signaling through SAP.62 Thus, on one hand, impaired signaling 
through 2B4 caused by SAP deficiency underlies defective cytolytic responses of CD8+ T and NK cells to EBV 
in X-linked lymphoproliferative syndrome,46, 47 whereas on the other hand, overexpression or extensive cross-
linking of 2B4 on cytotoxic cells results in inhibitory signaling.62 Thus a fine balance between inputs through 2B4 
needs to be achieved for 2B4 to function as an activating or inhibitory receptor, particularly with regard to fine-
tuning of the CD8+ T-cell response to antigen. In patients with PIK3CD GOF mutations, 2B4 expression was 
increased on CD8+ T cells, yet SAP expression was normal. Heightened expression of CD48 on primary B cells 
and LCLs from patients with PIK3CD GOF mutations invokes a scenario in which increased cross-linking of 2B4 
on CD8+ T and NK cells would result in inhibitory signaling through this receptor. Modulation of this axis might 
prove useful in conditions in which 2B4 or CD48 expression is increased. Indeed, blockade of 2B4/CD48 
interactions improved the in vitroeffector function of exhausted-type hepatitis B virus-specific CD8+ T cells.51  
Upregulation of PD-1 on CD8+ T cells and PD-1 ligands on B cells in patients with PIK3CD GOF mutations 
revealed additional mechanisms of impaired cytolytic function in patients with PIK3CD GOF mutations, with 
engagement of PD-1 restraining the function of CD8+ T cells.37, 38   This also raises the possibility that PD-1 
blockade, which improves or restores CD8+ T-cell function in mouse models of chronic viral infection,56 might be 
a therapeutic option to treat EBV viremia in patients with this disease. Such a proposition is supported by 
previous data from studies of HIV infection, in which CD8+ T cells acquire an exhausted phenotype similar to 
that observed for patients with PIK3CD GOF mutations.42, 43, 44, 45, 48     In vitro blockade of PD-1/PD-L1 
interactions with specific mAbs restored proliferation and effector function of CD8+ T cells in HIV+subjects.42, 
44, 45, 48  Remarkably, effector function of these cells was further improved by combined blockade of PD-1 and 
2B4.48   Thus it is plausible that checkpoint inhibitors, which have found such great success in cancer 
immunotherapy, could have application in treating PIK3CD GOF. However, although checkpoint inhibitor–type 
therapies for treating patients with PIK3CDGOF mutations can revert the phenotype and function of exhausted/ 
senescent CD8+ T cells in these subjects, their effects on the proinflammatory functions of immune cells would 
have to be closely monitored. 
 
Overall, CD8+ T cells in patients with PIK3CD GOF mutations, as well as a mouse model of this condition, 
present with features of accelerated differentiation, premature exhaustion, and/or immunosenescence with 
evidence of increased apoptosis and cytotoxic dysfunction accompanied by altered NK cell phenotype and 
defective cytotoxicity toward EBV-infected B cells. These observations parallel the aberrant expression of ligands 
for key regulatory molecules on B cells, highlighting the amenability of the CD48-2B4 and PD-1–PD-
L1/242,45,48,51 axes to immunotherapeutic intervention as an alternative or complement to current therapies, such as 
rapamycin 19, 20 or leniolisib.22   We are now also well placed to use our mouse model as a preclinical screen to test 
the efficacy of such putative therapeutics in restoring defects in CD8+ T-cell development and differentiation 
caused by hyperactive PI3K signaling. 
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GOF Gain-of-Function 
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Figure 1 
 
 
 
 
 
TEM cell skewing of CD8+ T lymphocytes in patients with PIK3CD GOF mutations. PBMCs from healthy control subjects (n = 33) and 
patients with PIK3CD GOF mutations (n = 33) were labeled with mAbs against CD4, CD8, CCR7, and CD45RA. A, Representative 
histogram plots showing CD8 expression by lymphocytes from control subjects and patients with PIK3CD GOF mutations. B, Frequency 
of CD4+ or CD8+ T cells within the lymphocyte gate in control subjects and patients with PIK3CD GOF mutations. 
Each symbol corresponds to an individual donor or patient; the horizontal barrepresents the mean. C and D, Ratio of CD4+ to CD8+ T cells 
in all control subjects and patients with PIK3CD GOF mutations (Fig 1, C) or control subjects and patients with PIK3CD GOF mutations 
according to age (Fig 1, D). E and F, TN/TSCM (CCR7+CD45RA+), TCM (CCR7+CD45RA−), TEM (CCR7−CD45RA−), and 
TEMRA (CCR7−CD45RA+) CD8+ T cells were identified. Fig 1, E, Representative fluorescence-activated cell sorting plots of CD45RA- and 
CCR7-expressing populations in CD8+ T cells from control subjects and patients with PIK3CD GOF mutations. Fig 1, F, Frequency of 
TN/TSCM, TCM, TEM, and TEMRA CD8+ T cells in control subjects and patients with PIK3CD GOF mutations. Statistics were performed by 
using the t test with the Mann-Whitney test (Fig 1, B and C) or 2-way ANOVA (Fig 1, F). ***P < .01 and ****P < .0001. 
 
 
 
  
Figure 2 
 
 
 
 
 
CD8+ T cells in patients with PIK3CD GOF mutations acquire an exhausted-type phenotype. PBMCs from healthy control subjects and 
patients with PIK3CD GOF mutations were labeled with mAbsagainst CD8, CD45RA, CCR7, CD57, 2B4, NKG2D, CD95, KLRG1, PD-
1, CD38, HLA class I (HLA-ABC), and HLA class II (HLA-DR). A-J, Total CD8+ T cells, as well as TN/TSCM (CCR7+CD45RA+), 
TCM(CCR7+CD45RA−), TEM (CCR7−CD45RA−), and TEMRA (CCR7−CD45RA+) subsets, were delineated, and the frequency of each 
population expressing CD57 (Fig 2, A), CD95 (Fig 2, B), CD160 (Fig 2, C), or KLRG1 (Fig 2, D); relative expression of PD-1 (Fig 2, E); 
percentage of CD38+ cells (Fig 2, F); relative expression of HLA class I (Fig 2, G) and HLA class II (Fig 2, H); percentage of 2B4+ cells 
(Fig 2, I); and relative expression of NKG2D (Fig 2, J) were determined. Relative expression is depicted as the fold change in mean 
fluorescence intensity compared with either total or naive CD8+ T cells from healthy subjects. Values (n) in each panel represent numbers 
of healthy control subjects and patients with PIK3CD GOF mutations examined for each indicated surface marker. K, Coexpression of 
CD57, KLRG1, and 2B4 on CD8+ T cells. Statistics were performed by using 2-way ANOVA. *P < .05, **P < .01, ***P < .001, and 
****P < .0001. 
 
 
  
Figure 3 
 
 
 
 
EBV-specific CD8+ T cells exhibit perturbed expression of regulatory molecules in patients with PIK3CD GOF mutations. A and B, 
PBMCs from patients with PIK3CD GOF mutations (n = 14) and HLA-matched control subjects (n = 14) were incubated with specific 
EBV–peptide–MHC class I tetramer complexes (Table E1) together with mAbs against CD8, CD45RA, CCR7, CD57, 2B4, CD160, 
NKG2D, CD95, KLRG1, PD-1, or CD38. Fig 3, A, Frequency of EBV-specific CD8+ T cells in healthy subjects and patients with 
PIK3CD GOF mutations. Fig 3, B, Distribution of EBV tetramer-positive CD8+ T cells in TN/TSCM, TCM, TEM, and TEMRA CD8+ T-
cell populations in healthy control subjects and patients with PIK3CD GOF mutations. Statistics were performed by using 2-way 
ANOVA. C-J, Frequency of EBV-specific CD8+ T cells expressing CD57 (Fig 3, C), CD95 (Fig 3, D), CD160 (Fig 3, E), and KLRG1 (Fig 
3, F); relative expression of PD-1 (Fig 3, G); percentage expressing CD38 (Fig 3, H) and 2B4 (Fig 3, I); and relative expression of NKG2D 
(Fig 3, J) on EBV-specific CD8+ T cells from patients with PIK3CD GOF mutations and control subjects were determined. Relative 
expression is depicted as fold change compared with mean fluorescence intensity of EBV-specific CD8+ T cells from healthy donors. 
Statistics were performed by using t tests with Mann-Whitney tests. K, Coexpression of CD57, KLRG1, and 2B4 in EBV-specific CD8+ T 
cells. Statistics were performed by using 2-way ANOVA. *P < .05, **P < .01, ***P < .001, and ****P < .0001.  
Figure 4 
 
 
 
Altered functionality of CD8+ T cells and enhanced restimulation-induced cell death of TEM CD8+ T cells from patients with PIK3CD GOF 
mutations. A and B, PBMCs from healthy donors (n = 3-5) or patients with PIK3CD GOF mutations (n = 3-6) were labeled with 
carboxyfluorescein succinimidyl esterand stimulated in vitro in the absence (nil) or presence of mAbs specific for CD2, CD3, and CD28 
with or without IL-2 or PHA/IL-2. Proliferation was determined after 3 (Fig 4, A) or 5 (Fig 4, B) days by calculating the percentage of 
CD8+ T cells that have undergone 2 or more divisions. Values represent means ± SEMs. C and D, PBMCs from patients with PIK3CD 
GOF mutations (n = 5-8) and healthy control subjects (n = 5-8) were stained directly ex vivo with mAbs to CD8, CCR7, CD45RA, 
granzyme B, and perforin. Frequency of CD8+ T cells expressing granzyme B (Fig 4, C) or perforin (Fig 4, D). Statistics were performed 
by using 2-way ANOVA. E and F, Frequency of EBV tetramer-positive CD8+ T cells expressing granzyme B (Fig 4, E) or perforin (Fig 
4, F; n = 5). G-I, PBMCs from healthy control subjects (n = 6) and patients with PIK3CD GOF mutations (n = 6) were stimulated for 
14 hours in the absence or presence of PMA/ionomycin with Brefeldin A and monensin. Percentage cells expressing IFN-γ (Fig 4, G), 
CD107a (Fig 4, H), or IL-2 (Fig 4, I) were determined. Statistics were performed by using t tests with Mann-Whitney tests. J and K, 
Percentage lysis of autologous LCLs by EBV-specific CD8+ T cells from healthy control subjects and patients with PIK3CD GOF 
mutations. Each graph depicts data from experiments using cells from 2 different patients and control subject run in triplicates. Statistics 
were performed by using 2-way ANOVA. *P < .05, **P < .01, and ***P < .001. L-N, Sorted TEM and TEMRA cells from healthy donors and 
patients with PIK3CD GOF mutations (n = 3) were stimulated with anti-CD2/CD3/CD28 mAbs and IL-2 for 10 days. Cells were then 
restimulated with plate-bound α-CD3 mAb to induce RICD or α-CD95 mAb for 24 hours, and cell death was assessed by staining with 
Zombie dye. Fig 4, L, Percentage death of TEM and TEMRA cells stimulated with α-CD3. Fig 4, M, FASLG expression 4 hours after α-CD3 
mAb stimulation of sorted and activated TEM and TEMRA cell populations from patients with PIK3CD GOF mutations. Values represent 
mean ± SEM mRNA levels of PIK3CD GOF TEMand TEMRA cell populations relative to that expressed by corresponding cells from healthy 
control subjects (normalized to 1, as indicated by dotted line). Fig 4, N, Percentage death of TEM and TEMRA cells in response to 20 ng/mL 
α-CD95 mAb. Statistics were performed by using 2-way ANOVA. *P < .05. 
 
  
Figure 5 
 
 
 
 
Impaired cytotoxicity of NK cells from patients with PIK3CD GOF mutations against EBV-B cell targets. A-J, PBMCs from healthy 
donors (n = 4-5) and patients with PIK3CD GOF mutations (n = 4-5) were labeled with mAbs against CD3, CD56, CD57, CD158a/g/h, 
CD16, HLA class I, NKp44, granzyme B, perforin, NKG2A (CD159a) and KLRG1. Fig 5, A, Frequency of NK cells (CD3−CD56+) in 
healthy control subjects and patients with PIK3CD GOF mutations. Frequency of CD56bright and CD56dim NK cells expressing CD57 (Fig 
5, B) and CD158a/g/h (Fig 5, C) is shown. Relative expression of CD16 (Fig 5, D), HLA class I (HLA-ABC; Fig 5, E), NKp44 (Fig 5, F), 
granzyme B (Fig 5, G), perforin (Fig 5, H), frequency of NKG2A (CD159a; Fig 5, I); and relative expression of KLRG1 on CD56bright and 
CD56dim NK (Fig 5, J) cells from healthy control subjects and patients with PIK3CD GOF mutations are shown. Relative expression is 
presented as fold change over mean fluorescence intensity of CD56bright NK cells from healthy subjects. K and L, Percentage lysis of 
autologous LCLs by lymphokine-activated killer cells from patients with PIK3CD GOF mutations and healthy control subjects. Data are 
means ± SDs of experiments run in triplicates. Statistics were performed by using 2-way ANOVA. *P < .05, **P < .01, ***P < .001, and 
****P < .0001. 
 
 
 
 
  
Figure 6 
 
 
 
Modified ligand expression on B cells from patients with PIK3CD GOF mutations. A and B, Total peripheral blood B cells (Fig 6, A) or 
LCLs (Fig 6, B) from healthy subjects or patients with PIK3CD GOF mutations were either stained immediately (left-hand plots) or 
stimulated in the absence (nil) or presence of CD40 ligand (CD40L)/α-immunoglobulin (right-hand plots); after 3 days, cells were stained 
with mAbsto CD48, PD-L1, PD-L2, or CD70. Graphs depict fold change of mean fluorescence intensity of the indicated molecules on 
primary B cells or LCLs from patients with PIK3CD GOF mutations relative to unstimulated B cells or LCLs from healthy control 
subjects. Statistics were performed by using 2-way ANOVA. *P < .05, **P < .01, ***P < .001, and ****P < .0001. 
 
 
  
Figure 7 
 
 
 
Pik3cdE1020K mice exhibit phenotypic and functional defects in CD8+ T cells independent of infection. A-C, Spleens or blood from wild-
type (WT) and Pik3cdE1021K mice at various ages were stained to identify different CD8+ T-cell populations. Flow plots show representative 
staining of CD8+ T cells from 8 to 12 weeks (WT, n = 10; Pik3cd,E1021K n = 13; Fig 7, A) or 33-week-old mice (spleens, n = 11; blood, 
n = 6; Fig 7, B). Fig 7, C, Percentages of CD4+ T cells with a TN (CD44loCD62Lhi), TCM (CD44hiCD62Lhi), or TEM (CD44hiCD62Llo) 
phenotype are shown in graphs (plots show means ± SEMs). D, Naive CD8+ T cells were sorted from spleens of WT or Pik3cdE1021K mice 
and cultured for 4 days with anti-CD3 and anti-CD28. Cells were then restimulated with PMA/ionomycin and IFN-γ and TNF-α production 
assessed (plots show means ± SEMs, n = 4-5). Significant differences were determined by using multiple t tests or 2-way ANOVA. 
*P < .05, ***P < .001, and ****P < .0001. 
 
 
  
Figure E1 
 
 
 
Vβ use of T-cell subsets from patients with PIK3CD GOF mutations. Samples from healthy donors (n = 5) and patients with PIK3CD GOF 
mutations (n = 2) were stained with Vβ mAbs in conjunction with mAbs to CD8, CD45RA, and CCR7 to determine the breadth of Vβ use 
by CD8+ T-cell subsets in patients compared with control subjects: A, TN (CCR7+CD45RA+); B, TCM (CCR7+CD45RA−); C, 
TEM(CCR7−CD45RA−); and D, TEMRA (CCR7−CD45RA+). 
 
 
  
Figure E2 
 
 
 
Altered cytokine production by TEM and TEMRA cells from patients with PIK3CD GOF mutations. Aand B, Frequencies of total 
(Fig E2, A) or EBV-specific (Fig E2, B) CD8+ T cells expressing granzymeA or granzyme K from healthy control subjects and patients 
with PIK3CD GOF mutations. Statistics were performed by using 2-way ANOVA (Fig E2, A) or a t test and Mann-Whitney test  
(Fig E2, B). C and D, Sorted TEM or TEMRA CD8+ T cells were stimulated with anti-CD2, CD3, and CD28 mAbs. On day 5, cells were 
stimulated with PMA/ionomycin in the presence of Brefeldin A and monensin. Proportions of TEM(Fig E2, C) or TEMRA (Fig E2, D) 
cells expressing or secreting IFN-γ, IL-2, CD107a, granzyme B or perforin, or TNF was then determined. Statistics were determined by 
using a t test with the Mann-Whitney test. *P < .05 and **P < .01. 
  
Figure E3 
 
 
 
Expression of MHC and CD95 on primary B cells and LCLs in patients with PIK3CD GOF mutations. Peripheral blood B cells (A) or 
LCLs (B) were stained with mAbs to HLA class I (HLA-ABC), HLA class II (HLA-DR), or CD95 either ex vivo or after in vitro culture in 
the absence (nil) or presence of CD40L plus α-immunoglobulin. Ex vivo B cells were identified as CD20+ cells. Expression of the indicated 
ligands was calculated relative to the mean fluorescence of control B cells or LCLs (normalized to 1.0). Statistics were performed by using 
a t test with the Mann-Whitney test or 2-way ANOVA. *P < .05, **P < .01, ***P < .001, and ****P < .0001. 
 
Table 1 
Demographic of subjexts given a diagnosis of PIL3CD GOF mutations 
 
 
  
Table E1 
Peptide-MHC tetramers to identify EBV-sepecfic CD8* T cells 
 
HLA type Epitope sequence Protein origin Patients investigated 
A∗0201 GLCTLVAML BMLF-1280-288 11, 12, 14, 15, 19, 20 
A∗11∗ AVFDFKSDAK EBNA-3B246-253 7 
B∗0702 RPPIFIRRL EBNA-3A247-255 3, 5, 6 
B∗0801 FLRGRAYGL EBNA-3A325-333 2, 9 
B∗0801 RAKFKQLL BZLF-1190-197 2, 9 
B∗27 RRIYDLIEL EBNA-3C258-266 8 
 
*Immudex Copenhagen Denmark 
 
 
Table E2 
mAbs used for lymphocyte pehotyping 
 
Target Fluorochrome Clone Supplier 
CD3 BV786 UCHT1 BD Horizon 
CD4 BUV395 SK3 (Leu3a) BD Horizon 
CD4 BUV737 SK3 (Leu3a) BD Horizon 
CD8 APC-Cy7 RPA-T8 BioLegend 
CD8 BUV395 RPA-T8 BD Horizon 
CD16 APC-Cy7 3G8 BioLegend 
CD20 PB 2H7 BioLegend 
CD38 FITC HB7 eBioscience 
CD45RA PerCP-Cy5.5 HI100 eBioscience 
CD45RA BV605 HI100 BD Horizon 
CD48 FITC Tu145 BD PharMingen 
CD56 BV605 HCD56 BioLegend 
CD57 FITC NK-1 BD PharMingen 
CD70 APC 113-16 BioLegend 
CD95 PE-CF594 DX2 BD Horizon 
CD158a/g/h PerCP-Cy5.5 HP-MA4 eBioscience 
CD160 PE BY55 BioLegend 
CCR7 FITC 150503 R&D Systems 
CCR7 PE Cy7 G043H7 BioLegend 
2B4(CD244) PE eBioC1.7 eBioscience 
Granzyme B AF700 GB11 BD PharMingen 
HLA ABC APC–Fire 750 W6/32 BioLegend 
HLA DR PE-Cy7 G46-6 BD PharMingen 
KLRG1 APC REA261 Miltenyi Biotech 
NKG2A (CD94) PerCP-Cy5.5 DX22 BioLegend 
NKG2D PerCP-eFLuor710 1D11 eBioscience 
NKp44 PE-Cy7 p44-8 BioLegend 
PD-1 Biotin eBioJ105 eBioscience 
Perforin PE-Cy7 B-D48 BioLegend 
SA BV711 BV711 
 
BD Horizon 
 
AF, Alexa Fluor;  
APC, allophycocyanin;  
BV, Brilliant Violet;  
FITC, fluorescein isothiocyanate;  
PB, Pacific Blue;  
PE, phycoerythrin;  
PerCP, peridinin-chlorophyll-protein complex.  
Table E3 
mAbs used for muring lymphocyte phenotyping 
 
 
Target Fluorochrome Clone Supplier 
CD3 PerCP-Cy5.5 17A2 BD Horizon 
CD4 APC–eFluor 780 RM4-5 eBioscience 
CD8 PB 53-6.7 BD Horizon 
IFN-γ PE-Cy7 XMG1.2 BD Horizon 
TNF-α PE MP6-XT22 BioLegend 
CD62L APC MEL-14 BD Horizon 
CD62L BV605 MEL-14 BioLegend 
CD62L FITC MEL-14 eBioscience 
CD44 FITC IM7 BD Horizon 
CD44 BV605 IM7 BD Horizon 
CD45R/B220 FITC RA3-6B2 BD Horizon 
CD45R/B220 BV786 RA3-6B2 BD Horizon 
CD25 PE PC61 BD Horizon 
CD25 APC PC61 eBioscience 
 
 
 
AF, Alexa Fluor;  
APC, allophycocyanin;  
BV, Brilliant Violet;  
FITC, fluorescein isothiocyanate;  
PB, Pacific Blue;  
PE, phycoerythrin;  
PerCP, peridinin-chlorophyll-protein complex. 
 
 
 
